Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

Pharmacy benefits manager (PBM) RxPreferred has announced plans to offer the Humira biosimilar Yusimry through Mark Cuban Cost Plus Drugs – an online pharmacy launched by celebrity investor and ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.